Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients
2002

Levocarnitine for Chemotherapy Fatigue in Cancer Patients

Sample size: 50 publication Evidence: moderate

Author Information

Author(s): Graziano F, Bisonni R, Catalano V, Silva R, Rovidati S, Mencarini E, Ferraro B, Canestrari F, Baldelli A M, De Gaetano A, Giordani P, Testa E, Lai V

Primary Institution: Medical Oncology Unit, Hospital of Urbino, Italy

Hypothesis

Can levocarnitine supplementation improve chemotherapy-induced fatigue in non-anaemic cancer patients?

Conclusion

Levocarnitine supplementation may effectively alleviate chemotherapy-induced fatigue in non-anaemic cancer patients.

Supporting Evidence

  • Fatigue improved in 90% of patients after 1 week of treatment.
  • All patients achieved normal plasma carnitine levels after supplementation.
  • The mean FACT-F score increased significantly from 19.7 to 34.9 after treatment.

Takeaway

This study found that giving cancer patients a supplement called levocarnitine helped them feel less tired after chemotherapy.

Methodology

Patients received oral levocarnitine 4 g daily for 7 days and fatigue was assessed using the FACT-F questionnaire.

Potential Biases

Potential biases due to the lack of randomization and the specific patient selection criteria.

Limitations

The study did not include a control group for comparison and was conducted in a homogenous patient population.

Participant Demographics

Non-anaemic cancer patients undergoing chemotherapy, with a performance status of 0-1.

Statistical Information

P-Value

<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1038/sj.bjc.6600413

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication